Impact of COVID‒19 Pandemic on Clinical Pharmacology Trials in Japanese Subjects Conducted at Phase 1 Units in Japan or Overseas-Reference-Cited by-同舟云学术

Impact of COVID‒19 Pandemic on Clinical Pharmacology Trials in Japanese Subjects Conducted at Phase 1 Units in Japan or Overseas

Published:2024-05-31 Issue:3 Volume:55 Page:93-97
ISSN:0388-1601
Container-title:Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
language:en
Short-container-title:Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics

Author:

TSUCHIYA Saori¹,MUTO Chieko²,TATAMI Shinji³,FURUKAWA Megumi⁴,ZHU Tong⁵,GIRISH Sandhya⁶,YOSHITSUGU Hiroyuki¹,NAGAO Lee⁷

Affiliation:

1. Clinical Pharmacology, Clinical Pharmacology Development, Clinical Research, Japan Development MSD K.K.

2. Clinical Pharmacology & Bioanalytics, Pfizer R&D Japan

3. Clinical Pharmacology Department, Nippon Boehringer Ingelheim Co., Ltd., Kobe, Japan

4. Clinical Pharmacology Group, Data Science Department, Ikuyaku Integrated Value Development Division, MTPC

5. Clinical Pharmacology & Exploratory Development, Astellas Pharma Global Development, Inc.

6. Clinical Pharmacology Sciences, Gilead Sciences

7. Faegre Drinker Biddle & Reath LLP

Publisher

Japanese Society of Clinical Pharmacology and Therapeutics

Link

Reference8 articles.

2. 2) CDC. CDC SARS Response Timeline. ［https://www.cdc.gov/about/history/sars/timeline.htm （accessed 2023-03-10）］

3. 3) Medidata（2020）. COVID-19 and clinical trials: the Medidata perspective. 2020.